Physician
Bitran, Mauricio
Bitran, Mauricio was paid $28.28M by Medicaid between Jan 2018 and Dec 2024, across 192 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 27% of everything it billed.
33Billing provider infoBITRAN, MAURICIO
MIAMI BEACH, FL 33140
MIAMI BEACH, FL 33140
33aNPI1700990108assigned 08/19/2006
33bProvider typeObstetrics & Gynecology Physician
28Total paid$28.28M
24GClaims585,839
24DCodes billed192
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Obstetrics & Gynecology Physician providers in Florida
Rank by total paid#2 of 352
Median peer was paid$67K
This provider vs. median424×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 13,416 | $426K | |
| 2019 | 83,563 | $3.80M | |
| 2020 | 84,522 | $4.04M | |
| 2021 | 118,808 | $6.29M | |
| 2022 | 99,241 | $5.43M | |
| 2023 | 118,532 | $5.76M | |
| 2024incomplete | 67,757 | $2.54M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 27% | 103,736 | 86,880 | $7.70M |
| H1000 | Prenatal care, at-risk assessment | 23% | 95,205 | 66,493 | $6.47M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 13% | 47,041 | 39,594 | $3.77M |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 6.9% | 16,140 | 15,098 | $1.96M |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 3.8% | 9,931 | 8,464 | $1.08M |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 3.1% | 7,348 | 7,135 | $880K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 3.0% | 47,778 | 41,637 | $848K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.6% | 8,934 | 7,895 | $739K |
| 59410 | 1.4% | 380 | 376 | $409K | |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 1.3% | 3,501 | 3,178 | $374K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 1.3% | 2,914 | 2,781 | $369K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 1.3% | 4,990 | 3,927 | $355K |
180 more codes
| 59430 | 1.2% | 2,376 | $335K | |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | 1.1% | 15,809 | $302K |
| H1001 | Prenatal care, at-risk enhanced service; antepartum management | <1% | 1,465 | $272K |
| 99223 | Prolong inpt eval add15 m | <1% | 3,527 | $214K |
| 90461 | <1% | 14,777 | $157K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,803 | $118K |
| 90670 | <1% | 5,012 | $111K | |
| 90698 | <1% | 2,639 | $109K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 2,185 | $104K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,665 | $86K |
| 59515 | <1% | 66 | $82K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 655 | $75K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 5,241 | $72K |
| 99254 | <1% | 517 | $71K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,649 | $63K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 888 | $62K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 620 | $62K |
| 92552 | <1% | 5,307 | $61K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 1,147 | $56K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,804 | $46K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 6,881 | $45K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 338 | $42K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 6,581 | $38K |
| 99285 | Emergency room visit (most serious) | <1% | 314 | $37K |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | <1% | 15,246 | $33K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 2,475 | $31K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,499 | $30K |
| 97803 | <1% | 1,295 | $29K | |
| 97802 | <1% | 3,210 | $27K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 628 | $26K |
| G0270 | Medical nutrition therapy; reassessment and subsequent intervention(s) following second referral in same year for change in diagnosis, medical condition or treatment regimen (including additional hours needed for renal disease), individual, face to face with the patient, each 15 minutes | <1% | 3,365 | $26K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 4,474 | $26K |
| 81513 | <1% | 332 | $24K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 370 | $23K |
| 90686 | <1% | 9,420 | $21K | |
| 92587 | <1% | 1,581 | $19K | |
| 76801 | <1% | 246 | $18K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 1,210 | $18K |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 120 | $17K |
| 95117 | <1% | 4,169 | $16K | |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | <1% | 1,591 | $16K |
| 99496 | <1% | 62 | $15K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 150 | $15K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 225 | $14K |
| 99188 | <1% | 1,870 | $14K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 244 | $13K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 584 | $12K |
| 90716 | <1% | 411 | $11K | |
| H0049 | Alcohol and/or drug screening | <1% | 621 | $10K |
| 90671 | <1% | 125 | $9K | |
| 81025 | <1% | 1,867 | $9K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 135 | $9K |
| 87481 | <1% | 308 | $9K | |
| 76813 | <1% | 113 | $8K | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 302 | $8K |
| 90651 | <1% | 401 | $8K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 136 | $7K |
| 90677 | <1% | 258 | $7K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 350 | $6K |
| 81002 | <1% | 3,411 | $6K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,406 | $6K |
| 81003 | <1% | 6,321 | $6K | |
| 90710 | <1% | 131 | $5K | |
| 92567 | <1% | 967 | $5K | |
| 87631 | <1% | 79 | $5K | |
| 0071A | <1% | 138 | $4K | |
| 0072A | <1% | 115 | $4K | |
| 87428 | <1% | 253 | $4K | |
| 99459 | <1% | 579 | $4K | |
| 99401 | <1% | 156 | $3K | |
| 76857 | <1% | 100 | $3K | |
| 90707 | <1% | 453 | $3K | |
| 99050 | <1% | 963 | $3K | |
| 96127 | <1% | 2,820 | $3K | |
| 99385 | <1% | 84 | $3K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 127 | $2K |
| 99205 | Prolong outpt/office vis | <1% | 13 | $2K |
| 85018 | <1% | 2,790 | $2K | |
| 95165 | Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials | <1% | 71 | $2K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 181 | $2K |
| 90700 | <1% | 633 | $2K | |
| 96160 | <1% | 1,776 | $2K | |
| 90656 | <1% | 260 | $2K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 593 | $2K |
| 99383 | <1% | 15 | $1K | |
| 91300 | <1% | 83 | $1K | |
| 93976 | <1% | 18 | $1K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 412 | $1K |
| 0002A | <1% | 43 | $1K | |
| 36410 | <1% | 94 | $1K | |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 427 | $1K |
| 90680 | <1% | 1,767 | $1K | |
| 87081 | <1% | 638 | $919.35 | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 20 | $903.05 |
| 99051 | <1% | 87 | $889.59 | |
| 90734 | <1% | 69 | $866.00 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 19 | $814.00 |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 555 | $786.52 |
| 92558 | <1% | 221 | $779.09 | |
| 81007 | <1% | 462 | $756.35 | |
| 95024 | <1% | 51 | $746.48 | |
| 46600 | <1% | 47 | $745.45 | |
| 90697 | <1% | 45 | $733.06 | |
| 81000 | <1% | 769 | $568.47 | |
| 88141 | <1% | 27 | $560.42 | |
| 99000 | <1% | 8,657 | $531.67 | |
| 0001A | <1% | 27 | $520.00 | |
| 90633 | <1% | 1,038 | $485.28 | |
| 76536 | <1% | 15 | $463.50 | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 23 | $445.48 |
| 93294 | <1% | 131 | $420.30 | |
| 90619 | <1% | 31 | $368.73 | |
| 73565 | <1% | 717 | $332.25 | |
| 94010 | <1% | 16 | $322.58 | |
| 87070 | <1% | 74 | $312.11 | |
| 90688 | <1% | 195 | $306.53 | |
| 87420 | <1% | 215 | $302.77 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 27 | $298.12 |
| 99174 | <1% | 255 | $243.98 | |
| G0442 | Annual alcohol misuse screening, 5 to 15 minutes | <1% | 192 | $233.76 |
| 96161 | <1% | 242 | $214.57 | |
| 90685 | <1% | 138 | $199.64 | |
| 92551 | <1% | 6,020 | $194.93 | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 163 | $186.27 |
| A7003 | Administration set, with small volume nonfiltered pneumatic nebulizer, disposable | <1% | 217 | $185.63 |
| 1159F | <1% | 16 | $175.29 | |
| 93000 | <1% | 165 | $167.73 | |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | <1% | 214 | $158.31 |
| 99173 | <1% | 6,902 | $152.26 | |
| 90723 | <1% | 171 | $144.04 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 30 | $132.48 |
| 59025 | Fetal non-stress test | <1% | 247 | $112.15 |
| 80305 | <1% | 16 | $95.32 | |
| 90648 | <1% | 510 | $83.03 | |
| 99177 | <1% | 8,582 | $76.09 | |
| 93296 | <1% | 131 | $66.82 | |
| 90674 | <1% | 166 | $62.30 | |
| 90647 | <1% | 135 | $56.72 | |
| 2000F | <1% | 198 | $47.13 | |
| 90744 | <1% | 405 | $44.01 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 21 | $32.55 |
| 90713 | <1% | 245 | $31.97 | |
| A7015 | Aerosol mask, used with dme nebulizer | <1% | 217 | $22.49 |
| 73564 | <1% | 361 | $21.74 | |
| 99408 | <1% | 463 | $21.73 | |
| 73562 | <1% | 245 | $7.84 | |
| A4206 | Syringe with needle, sterile, 1 cc or less, each | <1% | 76 | $7.65 |
| 94760 | <1% | 205 | $5.78 | |
| 91307 | <1% | 240 | $0.55 | |
| S9451 | Exercise classes, non-physician provider, per session | 0% | 3,979 | $0.00 |
| 3008F | 0% | 7,173 | $0.00 | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | 0% | 556 | $0.00 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 56 | $0.00 |
| 36416 | 0% | 3,532 | $0.00 | |
| G8420 | Bmi is documented within normal parameters and no follow-up plan is required | 0% | 585 | $0.00 |
| 51798 | 0% | 144 | $0.00 | |
| 1111F | 0% | 292 | $0.00 | |
| 3074F | 0% | 30 | $0.00 | |
| 73560 | 0% | 625 | $0.00 | |
| 1036F | 0% | 498 | $0.00 | |
| 99058 | 0% | 1,260 | $0.00 | |
| G0136 | Administration of a standardized, evidence-based assessment of physical activity and nutrition, 5-15 minutes, not more often than every 6 months | 0% | 72 | $0.00 |
| 99070 | 0% | 333 | $0.00 | |
| G8754 | Most recent diastolic blood pressure < 90 mmhg | 0% | 40 | $0.00 |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 0% | 50 | $0.00 |
| 90696 | 0% | 26 | $0.00 | |
| 90620 | 0% | 14 | $0.00 | |
| 20610 | 0% | 57 | $0.00 | |
| 73502 | 0% | 62 | $0.00 | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 0% | 17 | $0.00 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 76 | $0.00 |
| 90672 | 0% | 36 | $0.00 | |
| S9470 | Nutritional counseling, dietitian visit | 0% | 461 | $0.00 |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 479 | $0.00 |
| 99497 | 0% | 31 | $0.00 | |
| J7610 | Albuterol, inhalation solution, compounded product, administered through dme, concentrated form, 1 mg | 0% | 62 | $0.00 |
| 1090F | 0% | 52 | $0.00 | |
| 90715 | 0% | 12 | $0.00 | |
| 90681 | 0% | 17 | $0.00 | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.